Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study

Fabiani, Claudia; Sota, Jurgen; Vitale, A.; Rigante, Donato; Emmi, Giacomo; Vannozzi, Lorenzo; Bacherini, Daniela; Lopalco, Giuseppe; Guerriero, Silvana; Gentileschi, Stefano; Capozzoli, Marco; Franceschini, Rossella; Frediani, Bruno; Gargiulo, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Cantarini, Luca

doi:10.1136/bjophthalmol-2017-310733

Cited by 46 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular involvement in BS represents a clinical issue in terms of morbidity and mortality , and optimal clinical management still remains a matter of debate . Anti‐TNF agents are increasingly reported as the treatment of choice for involvement of different organs in BS ; nevertheless, only few data are available on the role of TNF inhibition in BS patients with vascular involvement .…”

Section: Discussionmentioning

confidence: 99%

Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome

Emmi

Vitale

Silvestri

et al. 2018

Arthritis & Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome

Emmi

Vitale

Silvestri

et al. 2018

Arthritis & Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Later observational evidence confirmed the benefits of this treatment in BS-related uveitis. In four Italian multicenter observational studies, treatment with either ADA or IFX proved effective for the treatment of refractory retinal vasculitis (45,(94)(95)(96). In another recent observational study on 106 patients with uveitis, ADA was associated with high rates of ocular control, effective steroid tapering, and good preservation of visual acuity, also in the absence of concomitant DMARDs treatment (46).…”

Section: Second-line Treatmentsmentioning

confidence: 99%

Treating the Different Phenotypes of Behçet's Syndrome

et al. 2019

Self Cite

View full text Add to dashboard Cite

Behçet's syndrome (BS) is a multisystemic vasculitis, characterized by different clinical involvements, including mucocutaneous, ocular, vascular, neurological, and gastrointestinal manifestations. Based on this heterogeneity, BS can be hardly considered as a single clinical entity. Growing evidence supports that, within BS, different phenotypes, characterized by clusters of co-existing involvements, can be distinguished. Namely, three major BS phenotypes have been reported: (a) the mucocutaneous and articular phenotype, (b) the extra-parenchymal neurological and peripheral vascular phenotype, and (c) the parenchymal neurological and ocular phenotype. To date, guidelines for the management of BS have been focused on the pharmacological treatment of each specific BS manifestation. However, tailoring the treatments on patient's specific phenotype, rather than on single disease manifestation, could represent a valid strategy for a personalized therapeutic approach to BS. In the present literature review, we summarize current evidence on the pharmacological treatments for the first-, second-, and third-line treatment of the major BS phenotypes.

show abstract

“…More recently, anti-TNF-α antibodies have been emerging as valuable treatment for different organ involvements in BS patients [22][23][24][25][26][27][28][29]. Of note, we found in a recent retrospective study that the anti-TNF-α adalimumab (ADA), alone or associated with other traditional immunosuppressive treatments, was significantly more effective than disease-modifying anti-rheumatic drugs (DMARDs) alone in resolving venous thrombosis, either DVT or SVT [28].…”

Section: Immunosuppressive Treatment For Venous Thrombotic Events In mentioning

confidence: 99%

Behçet’s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects

Becatti

Emmi

Bettiol

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Behçet’s syndrome (BS) is a complex disease with different organ involvement. The vascular one is the most intriguing, considering the existence of a specific group of patients suffering from recurrent vascular events involving the venous and, more rarely, the arterial vessels. Several clinical clues suggest the inflammatory nature of thrombosis in BS, especially of the venous involvement, thus BS is considered a model of inflammation‐induced thrombosis. Unique among other inflammatory conditions, venous involvement (together with the arterial one) is currently treated with immunosuppressants, rather than with anti‐coagulants. Although many in‐vitro studies have suggested the different roles of the multiple players involved in clot formation, in‐vivo models are crucial to study this process in a physiological context. At present, no clear mechanisms describing the pathophysiology of thrombo‐inflammation in BS exist. Recently, we focused our attention on BS patients as a human in‐vivo model of inflammation‐induced thrombosis to investigate a new mechanism of clot formation. Indeed, fibrinogen displays a critical role not only in inflammatory processes, but also in clot formation, both in the fibrin network and in platelet aggregation. Reactive oxygen species (ROS)‐derived modifications represent the main post‐translational fibrinogen alterations responsible for structural and functional changes. Recent data have revealed that neutrophils (pivotal in the pathogenetic mechanisms leading to BS damage) promote fibrinogen oxidation and thrombus formation in BS. Altogether, these new findings may help understand the pathogenetic bases of inflammation‐induced thrombosis and, more importantly, may suggest potential targets for innovative therapeutic approaches.

show abstract

Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study

Abstract: ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy.

Cited by 46 publications

References 20 publications

Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome

Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome

Treating the Different Phenotypes of Behçet's Syndrome

Behçet’s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects

Contact Info

Product

Resources

About